KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesBeginning Cash BalanceCash from Financing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Esperion Therapeutics (ESPR) Change in Account Payables: 2011-2024

Historic Change in Account Payables for Esperion Therapeutics (ESPR) over the last 14 years, with Dec 2024 value amounting to $12.4 million.

  • Esperion Therapeutics' Change in Account Payables rose 122.72% to $2.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $42.7 million, marking a year-over-year increase of 394.29%. This contributed to the annual value of $12.4 million for FY2024, which is 43.26% up from last year.
  • Esperion Therapeutics' Change in Account Payables amounted to $12.4 million in FY2024, which was up 43.26% from $8.7 million recorded in FY2023.
  • Esperion Therapeutics' Change in Account Payables' 5-year high stood at $23.1 million during FY2020, with a 5-year trough of -$34.1 million in FY2021.
  • In the last 3 years, Esperion Therapeutics' Change in Account Payables had a median value of $8.7 million in 2023 and averaged $8.9 million.
  • Its Change in Account Payables has fluctuated over the past 5 years, first soared by 243.92% in 2020, then slumped by 247.58% in 2021.
  • Over the past 5 years, Esperion Therapeutics' Change in Account Payables (Yearly) stood at $23.1 million in 2020, then crashed by 247.58% to -$34.1 million in 2021, then surged by 116.43% to $5.6 million in 2022, then surged by 54.88% to $8.7 million in 2023, then surged by 43.26% to $12.4 million in 2024.